IPF clinical trial design and endpoints

PURPOSE OF REVIEW: There remains a dire need for therapies that impact the clinical course of patients with idiopathic pulmonary fibrosis (IPF). Indeed, there is a surge of interest in IPF therapeutics, with many candidate agents in various stages of development. Optimal design and implementation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Steven D., Meyer, Keith C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
INTERSTITIAL LUNG DISEASE: Edited by Francesco Bonella and Steven D. Nathan
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162322/
https://www.ncbi.nlm.nih.gov/pubmed/25022315
http://dx.doi.org/10.1097/MCP.0000000000000091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162322/
https://www.ncbi.nlm.nih.gov/pubmed/25022315
http://dx.doi.org/10.1097/MCP.0000000000000091

Ejemplares similares